Drug Profile

Nebivolol/valsartan

Alternative Names: Byvalson; Valsartan/nebivolol

Latest Information Update: 18 May 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Forest Laboratories
Developer AbbVie
Class Antihypertensives; Benzopyrans; Ethanolamines; Ischaemic heart disorder therapies; Tetrazoles
Mechanism of Action Angiotensin type 1 receptor antagonists; Beta 1 adrenergic receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Essential hypertension

Most Recent Events

08 May 2020 Allergan has been acquired and merged into AbbVie
07 Jun 2016 Registered for Essential hypertension in USA (PO) (First global approval)
07 Jun 2016 The US approved label of nebivolol/valsartan tablets carries a black box warning

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com